WebSep 10, 2024 · The placeholder filing put Grail's IPO at $100 million, but it is expected to bring in as much as $500 million. Here are some of the reasons why: STRATEGY Grail … WebSep 14, 2024 · Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC). This move precedes the company’s anticipated 2024 launch of a multi-cancer liquid biopsy screening test for use in asymptomatic …
How to buy Grail (GRAL) stock finder.com
Web1 day ago · 以下是 FIERCE Biotech 统计 的2024年全球范围内融资金额最高的11家生物技术公司,这11家公司在2024年的融资金额都在2亿美元及以上。. 1、Altos Labs. 融资 ... WebSep 10, 2024 · ILMN. sequencing technology. What Happened: It isn't immediately clear how much Grail plans to raise in the offering, or the number of shares it intends to sell. In the filing, the cancer research ... china without tibet and xinjiang
Illumina’s Acquisition of GRAIL Faces Another Roadblock
WebApr 11, 2024 · GRAIL will present results from an analytical validation of its research-use only technology solution to accelerate cancer research in the post-diagnosis setting, … WebSep 11, 2024 · GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ:ILMN) currently held separate from Illumina Inc. under the terms of the Interim Measures Order of the European Commission dated 29 October 2024. WebSep 9, 2024 · The Holy Grail in cancer diagnostics: GRAIL files for an estimated $500 million IPO. G RAIL, a developer of next-gen cancer screening tests, filed on Wednesday with the SEC to raise up to $100 ... grand and toy catalog